Cancer BiologybioRxivPreprint
Immunogenic tumor mass dormancy as a driver of persistent residual lesions in immunotherapy-treated melanoma
Yingxiao Shi, Zoltan Maliga, Tuulia Vallius…·Peter Karl Sorger
This study shows that immunogenic tumor mass dormancy, not cell-level quiescence, persists in residual melanoma lesions after immunotherapy, with active tumor cells and immune interactions.